Start with its own history
At 39.30×, AMED is 7.5% below its 8-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
39.30×
7.5% belowthe 8-observation annual average
Price and EPS in quote currency. Calculation details
Investors are paying 39.30 for every 1 of reported earnings per share.
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2024 | 68.78× | N/M |
| Dec 31, 2023 | N/M | N/M |
| Dec 31, 2022 | 22.89× | -9.4% |
| Dec 31, 2021 | 25.25× | -51.4% |
| Dec 31, 2020 | 52.01× | +23.1% |
| Dec 31, 2019 | 42.26× | +31.3% |
| Dec 31, 2018 | 32.17× | -45.1% |
| Dec 31, 2017 | 58.57× | +53.9% |
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2016 | 38.06× | N/M |
| Dec 31, 2015 | N/M | N/M |
| Dec 31, 2014 | 75.26× | N/M |
| Dec 31, 2013 | N/M | N/M |
| Dec 31, 2012 | N/M | N/M |
| Dec 31, 2011 | N/M | N/M |
| Dec 31, 2010 | 8.33× | -14.4% |
| Dec 31, 2009 | 9.74× | -22.7% |
| Dec 31, 2008 | 12.60× | -34.5% |
| Dec 31, 2007 | 19.25× | +2.5% |
| Dec 31, 2006 | 18.78× | -14.0% |
| Dec 31, 2005 | 21.85× | +6.1% |
| Dec 31, 2004 | 20.59× | +17.7% |
| Dec 31, 2003 | 17.49× | -73.9% |
| Dec 31, 2002 | 67.11× | +769.2% |
| Dec 31, 2001 | 7.72× | +54.0% |
| Dec 31, 2000 | 5.01× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
AMED This stockAmedisys, Inc. | 39.30× |
ONEM1Life Healthcare, Inc. | N/M |
ASTHAstrana Health, Inc. | 26.76× |
OLKOlink Holding AB (publ) | N/M |
PDCOPatterson Companies, Inc. | 15.66× |
SWTXSpringWorks Therapeutics, Inc. | N/M |
LHCGLHC Group, Inc. | 86.20× |
AXNXAxonex AI Group Limited | N/M |
MORMorphoSys AG | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 39.30×, AMED is 7.5% below its 8-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 3 positive peer ratios above is 26.76×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("AMED", "PE Ratio", "LQ")Share price 100.99 ÷ EPS 2.57 = 39.30×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Not supplied; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.